FDA's China Country Head On The Agency's Mission In China: An Interview With PharmAsia News
This article was originally published in The Pink Sheet Daily
Executive Summary
PharmAsia News' China and Australia bureaus spoke recently with FDA China Country Director Hickey about the mission of the China office and progress being made in China.
You may also be interested in...
Counterfeit Drugs Produced In China Still Threaten Chinese, U.S., Global Consumers
BEIJING - Unless China does more to crack down on counterfeiting and contamination in its pharmaceutical industry, the United States could see a repeat of Chinese-made drugs or raw components causing severe adverse reactions in American hospitals, according to a Washington, D.C.-based scholar
FDA Issues Warning Letters To Two Chinese Producers Of Adulterated Heparin: Could Prosecution Lie Ahead?
BEIJING - In a move that could ultimately lead to civil or criminal prosecution, U.S. FDA has issued warning letters to two Chinese producers of raw heparin that was discovered to be contaminated with a look-alike chemical
U.S. FDA Set To Strengthen Inspections Of Chinese Drugmakers, Search For Adulterants In Aftermath Of Heparin Deaths – CDER Official
BEIJING - As U.S. FDA leaders select inspectors to deploy across three new offices being set up in China, the organization is also preparing to ramp up the number of inspections and the level of scrutiny of Chinese drugmakers that export to the U.S